As the global prevalence of NASH continues to escalate, ongoing research and healthcare policy initiatives are essential to meet the growing demand for liver transplants and improve accessibility for patients. Non-alcoholic steatohepatitis (NASH) is a painful condition of Non-Alcoholic Fatty Liver Disease (NAFLD) characterized by damage and inflammation to the liver, resembling alcoholic liver disease but occurring in individuals who consume little to no alcohol. As NASH progresses, it can lead to cirrhosis and liver failure, necessitating a liver transplant as the only viable treatment option in advanced stages.
NASH is part of a spectrum unlike simple fatty liver (steatosis); NASH involves liver cell injury and inflammation, which can progress to fibrosis, cirrhosis, and, ultimately, liver failure. Risk factors include obesity, type 2 diabetes, hypertension, and dyslipidemia. The exact cause of NASH is unknown, but it is associated with metabolic syndrome and insulin resistance.
Indications For Liver Transplant In NASH Patients Liver transplantation becomes necessary for NASH patients to function correctly. Key indications include: Liver Transplant Process Outcomes And Prognosis Liver transplant outcomes for NASH patients are generally favourable, with survival rates comparable to those for other liver diseases. However, NASH can recur in the transplanted liver, primarily if underlying metabolic conditions are not managed.
Therefore, lifestyle modifications, including maint.